Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Conflicts of interest must be acknowledged with sincerity and earnestness and managed such that the conflict is eliminated or, at least, credibly mitigated.
AMA J Ethics. 2023;25(3):E186-193. doi:
10.1001/amajethics.2023.186.
An emerging medical ethics issue is whether to delay posting pathology reports to electronic health records (EHR) to allow clinicians time to follow up.
AMA J Ethics. 2016;18(8):826-832. doi:
10.1001/journalofethics.2016.18.8.pfor1-1608.
Physicians should not only avoid forming personal relationships with drug reps but must also acquire and apply numeracy skills and information management strategies to critically evaluating drug reps’ information.
AMA J Ethics. 2015;17(8):729-733. doi:
10.1001/journalofethics.2015.17.8.ecas1-1508.